Net Income
Net Income
Royalty Pharma Net Income increased by 37.6% to $294.69M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 23.1%, from $239.35M to $294.69M. Over 3 years (FY 2021 to FY 2025), Net Income shows an upward trend with a 7.6% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementIncome Statement
SectionNet Income
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ1 2014
Last reportedQ1 2026
How to read this metric
Higher values indicate greater profitability and financial health, directly impacting shareholder value.
Detailed definition
The final bottom-line profit of the company after all operating expenses, non-operating expenses, and income taxes have...
Peer comparison
The most common metric for evaluating company performance against industry competitors.
Metric ID:
net_incomeHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $440.78M | $101.93M | $7.90M | $51.76M | $304.50M | $142.65M | $340.76M | $227.63M | $72.11M | $494.34M | $4.78M | $102.00M | $543.99M | $208.21M | $239.35M | $30.18M | $288.22M | $214.21M | $294.69M |
| QoQ Change | — | -76.9% | -92.2% | +554.9% | +488.3% | -53.2% | +138.9% | -33.2% | -68.3% | +585.5% | -99.0% | >999% | +433.3% | -61.7% | +15.0% | -87.4% | +855.1% | -25.7% | +37.6% |
| YoY Change | — | — | — | — | -30.9% | +40.0% | +558.3% | -25.2% | -49.4% | — | -98.6% | -55.2% | +654.3% | -57.9% | >999% | -70.4% | -47.0% | +2.9% | +23.1% |
Range$4.78M – $543.99M
CAGR-8.6%
Avg YoY Growth+411.0%
Median YoY Growth-28.1%
Net Income at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's net income?
- Royalty Pharma (RPRX) reported net income of $294.69M in Q1 2026.
- How has Royalty Pharma's net income changed year-over-year?
- Royalty Pharma's net income increased by 23.1% year-over-year, from $239.35M to $294.69M.
- What is the long-term trend for Royalty Pharma's net income?
- Over 3 years (2021 to 2025), Royalty Pharma's net income has grown at a 7.6% compound annual growth rate (CAGR), from $619.73M to $771.95M.
- What does net income mean?
- The total profit remaining after all costs, expenses, and taxes have been paid.